WO2008034202A3 - Use of ivermectin and derivates thereof for the treatment of amyotrophic lateral sclerosis - Google Patents

Use of ivermectin and derivates thereof for the treatment of amyotrophic lateral sclerosis Download PDF

Info

Publication number
WO2008034202A3
WO2008034202A3 PCT/BE2007/000107 BE2007000107W WO2008034202A3 WO 2008034202 A3 WO2008034202 A3 WO 2008034202A3 BE 2007000107 W BE2007000107 W BE 2007000107W WO 2008034202 A3 WO2008034202 A3 WO 2008034202A3
Authority
WO
WIPO (PCT)
Prior art keywords
lateral sclerosis
amyotrophic lateral
ivermectin
derivates
treatment
Prior art date
Application number
PCT/BE2007/000107
Other languages
French (fr)
Other versions
WO2008034202A2 (en
Inventor
Maria Andries
Wim Robberecht
Den Bosch Ludo Van
Original Assignee
Univ Leuven Kath
Maria Andries
Wim Robberecht
Den Bosch Ludo Van
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leuven Kath, Maria Andries, Wim Robberecht, Den Bosch Ludo Van filed Critical Univ Leuven Kath
Publication of WO2008034202A2 publication Critical patent/WO2008034202A2/en
Publication of WO2008034202A3 publication Critical patent/WO2008034202A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Present invention is directed to a novel medicament for medical treatment of motor neuron disease (NMD) such as amyotrophic lateral sclerosis. More particularly the present invention involves the use of ivermectin and analogues, to prevent, retard and ameliorate a motor neuron disease (MND) such as amyotrophic lateral sclerosis (ALS) and the associated motor neuron degeneration.
PCT/BE2007/000107 2006-09-19 2007-09-19 Use of ivermectin and derivates thereof for the treatment of amyotrophic lateral sclerosis WO2008034202A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0618403.0 2006-09-19
GBGB0618403.0A GB0618403D0 (en) 2006-09-19 2006-09-19 Treatment of amyotrophic lateral sclerosis

Publications (2)

Publication Number Publication Date
WO2008034202A2 WO2008034202A2 (en) 2008-03-27
WO2008034202A3 true WO2008034202A3 (en) 2008-06-19

Family

ID=37421218

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BE2007/000107 WO2008034202A2 (en) 2006-09-19 2007-09-19 Use of ivermectin and derivates thereof for the treatment of amyotrophic lateral sclerosis

Country Status (2)

Country Link
GB (1) GB0618403D0 (en)
WO (1) WO2008034202A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9351988B2 (en) 2011-05-02 2016-05-31 Universite De Geneve Macrocyclic lactones and use thereof
CN103356687B (en) 2012-10-19 2016-06-01 厦门大学 The purposes of a kind of ivermectin and derivative thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992022302A1 (en) * 1991-06-07 1992-12-23 Fractal Laboratories, Incorporated Treatment of human diseases involving dysregulation or dysfunction of the nervous system
FR2790670A1 (en) * 1999-03-12 2000-09-15 Aventis Pharma Sa Treatment or prevention of amyotrophic lateral sclerosis, using synergistic combination of riluzole and AMPA receptor antagonist, e.g. 5H,10H-imidazo (1,2-a) indeno (1,2-e) pyrazin-4-one derivative
JP2002047206A (en) * 2000-07-28 2002-02-12 Taisho Pharmaceut Co Ltd Accelerator for gdnf production, therapeutic agent for parkinson's disease and therapeutic agent for als
US20060205757A1 (en) * 2005-03-11 2006-09-14 Mingqiang Zhang 39-desmethoxyrapamycin, compositions and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992022302A1 (en) * 1991-06-07 1992-12-23 Fractal Laboratories, Incorporated Treatment of human diseases involving dysregulation or dysfunction of the nervous system
FR2790670A1 (en) * 1999-03-12 2000-09-15 Aventis Pharma Sa Treatment or prevention of amyotrophic lateral sclerosis, using synergistic combination of riluzole and AMPA receptor antagonist, e.g. 5H,10H-imidazo (1,2-a) indeno (1,2-e) pyrazin-4-one derivative
JP2002047206A (en) * 2000-07-28 2002-02-12 Taisho Pharmaceut Co Ltd Accelerator for gdnf production, therapeutic agent for parkinson's disease and therapeutic agent for als
US20060205757A1 (en) * 2005-03-11 2006-09-14 Mingqiang Zhang 39-desmethoxyrapamycin, compositions and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDRIES ET AL: "Ivermectin inhibits AMPA receptor-mediated excitotoxicity in cultured motor neurons and extends the life span of a transgenic mouse model of amyotrophic lateral sclerosis", NEUROBIOLOGY OF DISEASE, BLACKWELL SCIENCE, OXFORD, GB, vol. 25, no. 1, 21 November 2006 (2006-11-21), pages 8 - 16, XP005727015, ISSN: 0969-9961 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; TAKI, SHIGEYUKI ET AL: "V-type ATPase inhibitors as GDNF formation promoters for treatment of Parkinson disease and ALS (amyotrophic lateral sclerosis )", XP002474492, retrieved from STN Database accession no. 2002:113136 *

Also Published As

Publication number Publication date
WO2008034202A2 (en) 2008-03-27
GB0618403D0 (en) 2006-11-01

Similar Documents

Publication Publication Date Title
WO2007104789A3 (en) Amylin derivatives
WO2007109024A3 (en) Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
WO2007128802A3 (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
HK1215960A1 (en) Improved modalities for the treatment of degenerative diseases of the retina
WO2009043522A3 (en) Use of a peptide as a therapeutic agent
WO2007048801A3 (en) Sexual desire enhancing medicaments comprising benzimidazolone derivatives
UA94580C2 (en) 39-desmethoxyrapamycin analogue with increased blood-brain barrier permeability for the treatment of a medical condition resulting from neural injury or disease
WO2007127263A3 (en) Therapeutic uses of urolithins
WO2008043544A8 (en) Sulfonamide substituted pyrazoline compounds, their preparation and use as cb1 modulators
WO2009002159A3 (en) Intradermal hpv peptide vaccination
EP2139460A4 (en) Compositions and methods for the diagnosis, treatment, and prevention of amyotrophic lateral sclerosis and related neurological diseases
WO2009074247A8 (en) Novel 2-aryl-thiazole-4-carboxamide derivatives, production thereof, and use thereof as a medicament
WO2007135426A3 (en) Treatment of neurodegeneratives diseases
WO2007009686A3 (en) Substituted pyrazoline compounds, their preparation and use as medicaments
CA2646419C (en) Use of the long pentraxin ptx3 for the prevention or treatment of viral diseases
WO2008043788A3 (en) Novel compounds
WO2005023833A3 (en) Treatment of neurodegenerative diseases
WO2008152068A3 (en) [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases
WO2007147868A3 (en) Prevention of muscle atrophy
WO2006002846A3 (en) New analogs of nitrobenzylthioinosine
WO2008034202A3 (en) Use of ivermectin and derivates thereof for the treatment of amyotrophic lateral sclerosis
WO2007115287A3 (en) Combination of organic compounds
WO2009074498A8 (en) Medical use of 3- (2, 2, 2-trimethylhydrazinixm) propionate orotate
WO2009043525A3 (en) Use of the combination of gluten exorphin c and cd36 as a therapeutic agent
WO2006125818A3 (en) Oral pharmaceutical formulation for the prevention and/or the treatment of cardiovascular and inflammatory diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07815686

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07815686

Country of ref document: EP

Kind code of ref document: A2